Showing results (171-180 of 457) with videos related to
Sort By:
Pageof 46
Deutsche Medizinische Wochenschrift (1946)|December 19, 1986
[Therapy of primary resistant or recurrent small cell bronchial carcinoma with vindesine and ifosfamide]H Höfeler, K Höffken, N Niederle, et al.Physical Review Letters|August 11, 2005
Constraining the spectrum of supernova neutrinos from nu-process induced light element synthesisTakashi Yoshida, Toshitaka Kajino, Dieter H HartmannFEBS Letters|September 6, 1993
beta-Amyloid protein enhances the mitogen-induced calcium response in circulating human lymphocytesA Eckert, H Hartmann, W E MüllerLife Sciences|January 1, 1994
Disturbances of the neuronal calcium homeostasis in the aging nervous systemH Hartmann, A Eckert, W E MüllerNeuroscience Letters|April 2, 1993
Aging enhances the calcium sensitivity of central neurons of the mouse as an adaptive response to reduced free intracellular calciumH Hartmann, A Eckert, W E MüllerCancer Treatment Reports|October 1, 1986
Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancerK Höffken, H Kempf, A A Miller, et al.Bone Marrow Transplantation|November 9, 2004
Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCTS Scholl, L O Mügge, M Charbel Issa, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
Treatment of high-risk, nonseminomatous testicular cancer with cisplatin, ifosfamide and bleomycin: long-term resultsU B Wandl, K Günzel, R Kath, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controlsM Raida, W Schwabe, P Häusler, et al.Cancer Immunology, Immunotherapy : CII|October 1, 1993
Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB studyA Lindemann, P Brossart, K Höffken, et al.Pageof 46